Octreotide
Also known as Sandostatin, SMS 201-995
Octreotide (Sandostatin) is an approved injection that mimics somatostatin to dial down excess hormones — used for acromegaly (too much growth hormone) and certain hormone-secreting tumors.
How one dose clears
modeled over ~6 half-lives- Half-life
- 1.7 h
- Time to peak (Tmax)
- 24 min
- Bioavailability
- 100%
- Typical dose
- 50 mcg
Long-acting somatostatin analog for acromegaly and neuroendocrine-tumor symptoms (carcinoid, VIPoma). Immediate-release is dosed 2–3×/day SC.
Mechanism of action
Agonizes somatostatin receptors (mainly SSTR2/5), suppressing GH, glucagon, insulin and various gut hormones.
Approved drug. PK here is immediate-release SC (~1.7 h); the long-acting depot (LAR) releases over weeks and is not modeled by this curve. Can cause gallstones and alter glucose.
References
Track Octreotide for free
Log your doses and PeptideBuddy models Octreotide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.